Shares of Pacira Pharmaceuticals (NASDAQ: PCRX) tumbled 5.46% in after-hours trading on Tuesday following the release of its second-quarter 2025 financial results. The biopharmaceutical company's performance fell short of market expectations in key areas, prompting a negative reaction from investors.
Pacira reported total revenues of $181.1 million for the quarter, missing the analyst consensus estimate of $183 million. This represents a marginal increase of 1.73% compared to the same period last year. Despite the revenue miss, the company's adjusted earnings per share (EPS) of $0.74 beat the estimated $0.71, showcasing some resilience in its bottom line.
However, investors seemed more concerned about Pacira's net loss of $4.8 million for the quarter and its decision to narrow its full-year 2025 revenue guidance. The company now expects total revenue between $730 million and $750 million, down from the previous range of $725 million to $765 million. This adjustment, coupled with the Q2 performance, appears to have dampened market sentiment, leading to the significant after-hours decline in stock price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.